[ad_1]
Doctor Farhat Khanim, of the University of Birmingham, noted: “The development of new more infectious COVID-19 variants has results in the a rapid expansion in infection rates and deaths in several counties around the world, especially the UK, US and Europe.
“While vaccine programmes will hopefully reduce infection rates and virus spread in the longer term, there is still an urgent need to expand our arsenal of drugs to treat COVID-19 positive patients.”
Co-corresponding author Dr Alan Richardson, of Keele University, added: “Whilst in some countries vaccination programmes are progressing at speed, vaccine uptake rates are variable and for most low middle income countries, significant proportions of the population are unlikely to be vaccinated until 2022.
“Furthermore, whilst vaccination has been shown to reduce infection rates and severity of disease, we are as yet unsure of the strength and duration of the response. Therapies are still urgently needed to manage COVID-19 patients who develop symptoms or require hospitalisations.”
[ad_2]
